The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.

IF 2.4 Q2 DERMATOLOGY Current Dermatology Reports Pub Date : 2023-01-01 Epub Date: 2023-04-03 DOI:10.1007/s13671-023-00385-w

Nicole Maynard, April W Armstrong

{"title":"The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.","authors":"Nicole Maynard, April W Armstrong","doi":"10.1007/s13671-023-00385-w","DOIUrl":null,"url":null,"abstract":"Purpose of review: Immune-modulating treatments are used in dermatology for a variety of conditions. The authors aim to review the data regarding the safety of these treatments during the COVID-19 pandemic, namely the risk of infection with SARS-CoV-2 and the outcomes associated with COVID-19-related illness.Recent findings: Several large-scale studies found no increased risk of COVID-19 infection for patients on TNF-α inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, dupilumab, and methotrexate. They also found that these patients did not have worse outcomes when infected with COVID-19. The data regarding JAK inhibitors, rituximab, prednisone, cyclosporine, mycophenolate mofetil, and azathioprine are more mixed.Summary: Based on current research and guidelines from the American Academy of Dermatology and the National Psoriasis Foundation, dermatology patients on immune-modulating therapies can continue treatment during the COVID-19 pandemic when they are not infected with SARS-CoV-2. For patients who have COVID-19, guidelines encourage individualized assessment of the benefits and risks of continuing or temporarily withholding treatment.","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"12 2","pages":"45-55"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068706/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13671-023-00385-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Immune-modulating treatments are used in dermatology for a variety of conditions. The authors aim to review the data regarding the safety of these treatments during the COVID-19 pandemic, namely the risk of infection with SARS-CoV-2 and the outcomes associated with COVID-19-related illness.

Recent findings: Several large-scale studies found no increased risk of COVID-19 infection for patients on TNF-α inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, dupilumab, and methotrexate. They also found that these patients did not have worse outcomes when infected with COVID-19. The data regarding JAK inhibitors, rituximab, prednisone, cyclosporine, mycophenolate mofetil, and azathioprine are more mixed.

Summary: Based on current research and guidelines from the American Academy of Dermatology and the National Psoriasis Foundation, dermatology patients on immune-modulating therapies can continue treatment during the COVID-19 pandemic when they are not infected with SARS-CoV-2. For patients who have COVID-19, guidelines encourage individualized assessment of the benefits and risks of continuing or temporarily withholding treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

皮肤病免疫调节治疗对感染SARS-CoV-2的风险和与新冠肺炎疾病相关的结果的影响。

综述目的：免疫调节治疗在皮肤科用于各种疾病。作者旨在审查新冠肺炎大流行期间这些治疗的安全性数据，即感染SARS-CoV-2的风险和与新冠肺炎相关疾病相关的结果。最近的发现：几项大规模研究发现，使用TNF-α抑制剂、IL-17抑制剂、IL-12/23抑制剂、IL-23抑制剂、dupilumab和甲氨蝶呤的患者感染新冠肺炎的风险没有增加。他们还发现，这些患者在感染新冠肺炎时并没有出现更糟糕的结果。关于JAK抑制剂、利妥昔单抗、泼尼松、环孢菌素、霉酚酸酯和硫唑嘌呤的数据更为混杂。摘要：根据美国皮肤病学会和国家牛皮癣基金会的最新研究和指南，在新冠肺炎大流行期间，接受免疫调节疗法的皮肤病患者如果没有感染SARS-CoV-2，可以继续治疗。对于患有新冠肺炎的患者，指南鼓励对继续或暂时停止治疗的益处和风险进行个性化评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Dermatology Reports DERMATOLOGY-

CiteScore

3.30

自引率

6.20%

发文量

期刊介绍： This journal intends to review the most significant recent developments in the field of dermatology. By providing clear, insightful, balanced contributions by expert international authors, the journal aims to serve all those involved in the diagnosis, treatment, management, and prevention of dermatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field, such as epidemiology, surgery, pharmacology, clinical trial design, and pediatrics. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known figures in the field, and an Editorial Board of more than 20 internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.

期刊最新文献

Skin Type Diversity in Skin Lesion Datasets: A Review. Teledermatology Lessons During the COVID-19 Pandemic Mpox: Diagnosis and Management for the Inpatient Dermatologist Inpatient Evaluation and Management of Generalized Pustular Dermatoses Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist